Recurrent Rectal Cancer Clinical Trial
Official title:
A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU
Verified date | May 2013 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for colorectal cancer.
Status | Completed |
Enrollment | 560 |
Est. completion date | |
Est. primary completion date | December 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed locally advanced, locally recurrent,or metastatic colorectal adenocarcinoma not curable by surgery or radiotherapy - Progressive disease following: - One prior fluorouracil based chemotherapy regimen for metastatic disease - Failure during or within 6 months after fluorouracil based adjuvant therapy - Measurable or evaluable disease - No CNS metastases or carcinomatous meningitis - Performance status - ECOG 0-2 - At least 12 weeks - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 9 g/dL (transfusion allowed) - Bilirubin no greater than 1.5 mg/dL - AST no greater than 5 times upper limit of normal (ULN) - Alkaline phosphatase no greater than 5 times ULN - Creatinine no greater than 1.5 times ULN - No uncontrolled high blood pressure - No unstable angina - No symptomatic congestive heart failure - No myocardial infarction with the past 6 months - No serious uncontrolled cardiac arrhythmias - No New York Heart Association class III or IV heart disease - No pleural effusion or ascites that cause respiratory compromise (e.g., dyspnea grade 2 or greater) - No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung - Not pregnant or nursing - Fertile patients must use effective contraception - Fluent in English - No active or uncontrolled infection - No other prior malignancy within the past 5 years, except: - Adequately treated basal or squamous cell skin cancer - Adequately treated noninvasive carcinomas - No sensory neuropathy grade 2 or greater - No uncontrolled colonic or small bowel disorders (greater than 3 loose stools daily) - No concurrent sargramostim (GM-CSF) - At least 4 weeks since prior chemotherapy and recovered - No more than 1 prior chemotherapy regimen for advanced colorectal cancer - No prior irinotecan or other camptothecin derivative (e.g., topotecan) - No prior oxaliplatin - No other concurrent investigational chemotherapy agents - At least 4 weeks since prior major radiotherapy - No prior radiotherapy to greater than 25% of bone marrow - At least 4 weeks since prior major surgery and recovered - At least 2 weeks since prior minor surgery and recovered |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | North Central Cancer Treatment Group | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | Eastern Cooperative Oncology Group, Southwest Oncology Group |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival | The primary analysis for this trial will be based on a one-sided Generalized Wilcoxon test. | At least 6 months | No |
Secondary | Time-to-tumor progression | Time from start of therapy to documentation of disease progression, assessed up to 3 years | No | |
Secondary | Time-to-treatment failure | Time from the date of randomization to the date at which the patient is removed from treatment due to progression, toxicity, refusal, or death, assessed up to 3 years | No | |
Secondary | Objective tumor response rate (CR or PR) in patients with measureable disease | At least 4 weeks | No | |
Secondary | Toxicity and dose intensity | Up to 3 years | Yes | |
Secondary | Quality of life | Up to 3 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01987726 -
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
|
||
Active, not recruiting |
NCT00826540 -
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00025337 -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
|
Phase 3 | |
Recruiting |
NCT04642924 -
SGM-101 in Locally Advanced and Recurrent Rectal Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01217450 -
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01285102 -
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
|
Phase 1 | |
Terminated |
NCT01238965 -
Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00551421 -
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00407654 -
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
Terminated |
NCT00052585 -
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00023933 -
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05076305 -
PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
|
||
Completed |
NCT01740648 -
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
|
Phase 1 | |
Terminated |
NCT00397878 -
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
|
Phase 2 | |
Completed |
NCT00100841 -
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
|
Phase 2 |